Life Threatening Diseases Clinical Trial
Official title:
Bilateral Retinal Embolic Phenomena Always Necessitates Immediate and Intensive Investigation. Careful, Documented, Ophthalmic Examination is All we Require to Initiate Life Saving Investigations.
Verified date | April 2019 |
Source | Dr. S.S. Michel Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study shows how careful ophthalmic examination of two patients showed signs of simultaneous bilateral retinal emboli. Starting from this point significant, life threatening, underlying reasons were found and treated.
Status | Completed |
Enrollment | 2 |
Est. completion date | December 31, 2018 |
Est. primary completion date | January 29, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 80 Years |
Eligibility |
Inclusion Criteria: - any patient who is found to have sure signs of bilateral retinal emboli. Exclusion Criteria: - all other bilateral retinal diseases. |
Country | Name | City | State |
---|---|---|---|
Canada | Dr. S.S. Michel Clinic | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
Dr. Shawkat Michel |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The extreme significance of immediate investigation of cases of bilateral retinal emboli (non-diabetic bilateral posterior pole retinal nerve fiber or pre-retinal hemorrhages). | Patients that are noticed to have signs of bilateral retinal emboli (bilateral retinal nerve fiber layer hemorrhages or bilateral pre-retinal hemorrhages and sometimes bilateral soft exudates) may be asymptomatic or have very mild symptoms. However these patients must be immediately and, if needed, intensively investigated to find the source of these emboli. The extremely important point of this study is these patients usually have life threatening conditions that should be found out and treated in time. | through study completion, an average of one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00154388 -
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
|
Phase 2 |